ホーム › 転移性癌 › カリフォルニア州 › Mountain View
Mountain View、CAにおける転移性癌の臨床試験
Mountain Viewとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Stanford Cancer Institute Palo Alto, Palo Alto · 5マイル先
- VA Palo Alto Health Care System, Palo Alto · 5マイル先
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
被験者募集中第1/2相
- Stanford, Palo Alto · 5マイル先
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- Stanford Cancer Center, Palo Alto · 5マイル先
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
被験者募集中第3相
- Palo Alto Medical Foundation - Palo Alto Center, Palo Alto · 5マイル先
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
被験者募集中第1/2相
- Stanford Medicine, Palo Alto · 5マイル先
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
被験者募集中第1相
- Stanford Cancer Institute, Stanford · 5マイル先
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Stanford University Medical Center, Stanford · 5マイル先
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Stanford Women's Cancer Center, Palo Alto · 5マイル先
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Stanford Cancer Center, Palo Alto · 5マイル先
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Stanford Cancer Institute, Stanford · 5マイル先
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
被験者募集中第2相
- Stanford University, Palo Alto · 5マイル先
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
被験者募集中第3相
- Research Site, Palo Alto · 5マイル先
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
被験者募集中第1/2相
- Stanford Cancer Institute (SCI), Stanford · 5マイル先
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Stanford Medicine Cancer Center, Stanford · 5マイル先
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Stanford Cancer Institute, Stanford University, Palo Alto · 5マイル先
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
被験者募集中第3相
- Stanford University School of Medicine, Palo Alto · 5マイル先
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- Stanford Medicine Cancer Center, Stanford · 5マイル先
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
被験者募集中第1/2相
- Stanford Cancer Institute, Stanford · 5マイル先
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
被験者募集中第2/3相
- Stanford Health Care - Skin Cancer Program, Stanford · 5マイル先
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Stanford Cancer Institute, Palo Alto · 5マイル先
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
被験者募集中第1相
- Stanford Cancer Institute, Stanford · 5マイル先
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
被験者募集中第1相
- Stanford Cancer Institute, Stanford · 5マイル先
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
被験者募集中観察研究
- VA Palo Alto Healthcare System, Palo Alto · 5マイル先
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
被験者募集中第1相
- Stanford Cancer Institute, Palo Alto · 5マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Stanford · 5マイル先
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Mountain Viewにおける他の研究
- がん（全種類）40件の研究
- 乳がん26件の研究
- 非小細胞肺癌21件の研究
- 急性骨髄性白血病19件の研究
- 卵巣がん19件の研究
- 自閉スペクトラム症17件の研究
- 肺がん17件の研究
- 前立腺がん15件の研究
- 心不全15件の研究
- 自閉症13件の研究
- 急性リンパ性白血病13件の研究
- 大腸癌13件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。